Zantac manufacturer Novartis has stopped the distribution of its heartburn medication across all available markets, including the United States and Canada, Reuters reported.
The halt in distribution comes days after the FDA announced that it had found low levels of N-nitrosodimethylamine (NDMA), a possible human carcinogen, in the medication.
Novartis said in an emailed statement to Healio Gastroenterology and Liver Disease that the precautionary distribution stoppage of all ranitidine-containing medications will remain in place until further clarification.
“Our internal investigation is

Source link